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ABSTRACT 
Background: Diaphragmatic fatigue might contribute to the development of 
respiratory failure. In particular, the spontaneous, natural rate of phrenic nerve 
discharge occurs mainly in low-frequency ranges making low-frequency fatigue 
clinically important in both humans and animals. Olprinone, a phosphodi- 
esterase 3 inhibitor, improves contractility in fatigued iaphragm, but is also 
associated with hypotension. Dopamine might be used concomitantly for treat- 
ing related hypotension. 
Objective: The purpose of the study was to assess the effect of olprinone 
plus dopamine on diaphragmatic fatigue in pentobarbital-anesthetized dogs. 
Methods: This nonblinded study was conducted at the Department of 
Anesthesiology, Institute of Clinical Medicine, Tsukuba, Japan. Diaphragmatic 
fatigue (assessed by a decrease in diaphragmatic contractility) was induced by 
intermittent supramaximal bilateral electrophrenic stimulation at a frequency 
of 20 Hz applied for 30 minutes. Immediately after the fatigue-producing period, 
groups 2, 3, and 4 received an initial 10 1Jg/kg dose of olprinone. Group 2 then 
received maintenance olprinone of 0.3 1Jg/kg • min; group 3 received mainte- 
nance olprinone 0.3 1Jg/kg • min plus dopamine 2 1Jg/kg • min; and group 4 
received maintenance olprinone 0.3 1Jg/kg • min plus dopamine 5 1Jg/kg • min. 
Group 1 received no study drug. Olprinone and dopamine were administered IV 
for 30 minutes. Diaphragmatic contractility was assessed by measuring the max- 
imal transdiaphragmatic pressure (Pdi) generated by test stimuli after airway 
occlusion at functional residual capacity. Hypotension induced by the study 
drugs was defined as a >10 mm Hg decrease in mean arterial pressure (MAP), 
calculated by diastolic pressure plus 1/3 pulse pressure, from baseline. 
Results: Twenty-eight mongrel dogs (18 males and 10 females, weighing 10- 
15 kg) were used in the study; 7 dogs were randomly assigned to each treat- 
ment group. When fatigue was established in each group, mean (SD) Pdi at low- 
frequency (20 Hz) stimulation decreased significantly from baseline in all groups 
(group 1:15.6 [2.2] vs 11.7 [2.4] cm H20 , P = 0.008; group 2:15.4 [1.5] vs 11.6 
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[1.3] cm H20 ,P :  0.005; group 3:15.5 [2.0] vs 11.6 [1.8] cm H20 ,P :  0.006; group 4: 
15.7 [1.4] vs 12.0 [1.4] cm H20 , P = 0.008), while no significant change existed in 
Pdi at high-frequency (100 Hz) stimulation (P = NS). After study drug adminis- 
tration, Pdi in groups 2, 3, and 4 increased significantly from fatigued values at 
both 20 Hz stimulation (group 2:11.6 [1.3] vs 21.8 [2.0] cm H20 , P = 0.001; group 
3:11.6 [1.8] vs 22.2 [1.8] cm H20 , P = 0.001; group 4:12.0 [1.4] vs 25.9 [1.9] cm 
H20 , P = 0.001) and 100 Hz st imulation (group 2:22.0 [2.2] vs 29.0 [1.9] cm 
H20 , P = 0.002; group 3:22.1 [2.0] vs 29.3 [2.2] cm H20 , P = 0.002; group 4:21.8 
[2.2] vs 31.7 [2.4] cm H20 , P = 0.001). The increase in Pdi was significantly larger 
in group 4 compared with the other 3 groups (all, P < 0.05). Hypotension was 
not observed in group 4. MAP did not change significantly in group 1 or group 4 
compared with baseline or fatigued MAP values (P = NS). Groups 2 and 3 had 
significant decreases in MAP with treatment compared with values in group 1 and 
with baseline and fatigued MAP values (all, P< 0.05). The MAP of group 4 was sig- 
nificantly greater than the MAP of groups 2 and 3 with treatment (both, P< 0.05). 
Conclusions: Olprinone 0.3 pg/kg • min plus dopamine 5 pg/kg • min improved 
contracti l ity in fatigued diaphragms and was not associated with hypotension 
in these pentobarbital-anesthetized dogs. Olprinone monotherapy and olpri- 
none 0.3 pg/kg • min plus dopamine 2 pg/kg • min might improve contracti l ity sig- 
nificantly. However, it was also associated with significant decreases in MAP. 
(Curr TherRes Clm Exp. 2006;67:204-213) Copyright © 2006 Excerpta Medica, Inc. 
Key words: muscle, diaphragm, contractility, fatigue, olprinone, dopamine, 
dogs, animal study. 
INTRODUCTION 
The diaphragm is the most important inspiratory muscle in the respiratory 
pumping system. 1,2 Fatigue of respiratory muscles, especially diaphragmat- 
ic fatigue, has been associated with respiratory failure in a variety of pulmo- 
nary  diseases. Like methylxanthines,  [32-agonists, and digoxin, 3,4 phosphodi -  
esterase 3 inhibitors (amrinone, milrinone, and olprinone) are effective in the 
t reatment  of d iaphragmat ic  fatigue. 5-7 Among these phosphod ies terase  3 
inhibitors, olprinone is the most efficacious, 5-7 but high-dose (>0.3 pg/kg • min) 
olprinone causes hypotension by its direct relaxing effect on the vascular 
smooth muscle. 8This hypotension might increase the risk of organ dysfunction, 
including brain ischemia, myocardial ischemia, and decreased renal blood flow, 
especially in elderly or ill patients. 9 Dopamine directly stimulates c¢- and 
[3-adrenergic receptors; it is most often used in clinical situations character ized 
by decreased systemic blood pressure. 1° Therefore, dopamine might prevent 
hypotension induced by olprinone. Also, dopamine has been associated with 
an increase in diaphragmatic strength in patients with chronic obstructive 
pulmonary disease during treatment for acute respiratory failure. 11 However, 
based on a MEDLINE search (key words: olprmone, dopamine, muscle, dia- 
phragm, contractility, and fatigue; years: January 1990-February 2006), published 
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data regarding the possible effects of the combination of olprinone and 
dopamine on diaphragmatic fatigue in animals or humans was not found. 
This study was undertaken toassess the efficacy of olprinone plus dopamine 
in treating diaphragmatic fatigue in pentobarbital-anesthetized dogs. 
MATERIALS AND METHODS 
This study was conducted at the Department of Anesthesiology, Institute of 
Clinical Medicine, University of Tsukuba, Tsukuba, Japan. The protocol was ap- 
proved by our animal research committee, and the care of animals was conducted 
in agreement with guidelines for ethical animal research. 6,r The author, who was not 
blinded to treatment group, performed all measurements and analyses in the study. 
Adult (>5 years) mongrel dogs (provided by Animal Guidance Center, 
Mashiko, Japan) were randomly assigned to 1 of 4 study groups using a 
computer-generated (StatView, SAS Institute Inc., Tokyo, Japan) list of random 
numbers: group 1, no study drug; group 2, olprinone 0.3 lag/kg • min; group 3, 
olprinone plus dopamine 2 lJg/kg • min; and group 4, olprinone plus dopamine 
5 lJg/kg • min. 
Animal preparation was similar to that described previously, s-r Briefly, anes- 
thesia was maintained with IV pentobarbital 2 mg/kg • h. No muscle relaxant was 
used. Each dog's trachea was intubated, and ventilation was mechanically con- 
trolled with a mixture of oxygen and air (40% inspired oxygen) to maintain arte- 
rial partial pressure of oxygen >100 mm Hg, arterial partial pressure of carbon 
dioxide 35 to 40 mm Hg, and arterial pH 7.35 to 7.45. The right femoral artery 
was cannulated to monitor arterial blood pressure and the right femoral vein 
was cannulated to administer maintenance fluid. The left femoral vein was can- 
nulated to administer the study drugs (olprinone, dopamine). A flow-directed 
pulmonary artery catheter was advanced via the right external jugular vein into 
the pulmonary artery to measure cardiac output (CO) using the thermodilution 
technique. 12Transdiaphragmatic pressure (Pdi) was measured using 2 thin- 
walled latex balloons: 1 was positioned in the stomach and the other in the mid- 
dle third of the esophagus. The balloons were connected to a differential pressure 
transducer (TP 604T, Nihon Koden, Tokyo, Japan) and an amplifier (model 1257, 
Nihondenki San-ei, Tokyo, Japan). Phrenic nerves were exposed bilaterally at the 
neck, and stimulating electrodes were placed around them. Supramaximal electri- 
cal stimuli (10-15 V) of 0.1 ms duration were applied for 2 seconds at low 
frequency (20 Hz) and high frequency (100 Hz) with an electrical stimulator 
(SEN-3301, Nihon Koden). Diaphragmatic contractility was then assessed by mea- 
suring the maximal Pdi generated by the test stimuli after airway occlusion at func- 
tional residual capacity. Electrical activity of the diaphragm was recorded using 
2 pairs of fishhook electrodes. Activity signals from the diaphragm were rectified 
and integrated with an integrator (type 1322, Nohondenki San-ei) with a time con- 
stant of 0.1 second. This was regarded as the integrated activity of the crural 
(Edi-cru) and costal (Edi-cos0 parts of the diaphragm. 
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The dogs were allowed to stabilize for at least 30 minutes before study ini- 
tiation following animal preparation. Baseline measurements of Pdi, Edi-cru, 
Edi-cost, and hemodynamic variables (heart rate [HR], mean arterial pressure 
[MAP], right atrial pressure [RAP], mean pulmonary arterial pressure [MPAP], 
pulmonary artery occlusion pressure [PAOP], and CO) were recorded in each 
group. RAP, MPAP, and PAOP were measured by using a pulmonary artery 
catheter. Diaphragmatic fatigue was induced by intermittent supramaximal 
bilateral electrophrenic stimulation applied for 30 minutes at a frequency of 
20 Hz (entire cycle lasting for 4 seconds with a duty cycle of 0.5 second [ie, 
low-frequency fatigue]). 13 When fatigue was established (assessed by a de- 
crease in diaphragmatic contractility), groups 2, 3, and 4 received continuous 
IV olprinone (10 1Jg/kg initial dose plus 0.3 1Jg/kg • min maintenance dose) with an 
electrical infusion pump for 30 minutes. During olprinone administration, group 
3 received opamine 21Jg/kg • min and group 4 received opamine 5 1Jg/kg • min, 
both by IV infusion. 
Immediately after the cessation of study drug administration, Pdi, Edi-cru, 
Edi-cost, HR, MAP, RAP, MPAP, PAOP, and CO were measured. Though no study 
drug was administered to group 1, the same measurements were performed as 
in the other groups. Hypotension was defined as a >10 mm Hg decrease in MAP 
from baseline. The changes in Edi-cru (%Edi-cru) and Edi-cost (%Edi-cost) from 
baseline were also determined. 
Statistical Analysis 
Values are given as mean (SD). Statistical analyses were performed using 
analysis of variance for repeated measurements followed by the Bonferroni 
adjustment and Dunn test for multiple comparisons and the Student test, as 
appropriate. P < 0.05 was considered significant. A power analysis was per- 
formed to determine the number of animals needed in this experiment, based 
on the following: (1) improvement in contractility of fatigued iaphragm during 
study drug administration (primary end point); (2) occurrence of hypotension 
induced by study drug (secondary end point); and (3) c¢ = 0.05 with a power 
(1 - 13) = 0.8. Based on these requirements, a total of 7 dogs per group was de- 
termined to be sufficient. Analyses were performed using SPSS version 8.0 
(SPSS Inc., Chicago, Illinois). 
RESULTS 
Twenty-eight adult mongrel dogs (18 males and 10 females, weighing 10- 
15 kg) were included in the study; 7 dogs were assigned to each treatment 
group. No significant differences in baseline hemodynamic variables were 
observed among the groups. With an infusion of olprinone alone (group 2) or 
in combination with dopamine 2 1Jg/kg • min (group 3), HR and CO levels 
increased significantly (all, P < 0.05) while MAP, MPAP, and PAOP decreased 
significantly (all, P < 0.05) from baseline. After administering olprinone plus 
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dopamine 5 1Jg/kg • min (group 4), HR and CO increased significantly (HR: 142 
[11] vs 160 [11] bpm, P= 0.007; CO: 1.9 [0.2] vs 3.5 [0.2] L/min, P= 0.001), while 
there was no significant difference from baseline in MAP, MPAP, and PAOP (all, 
P = NS). Hypotension was not observed in group 4. No hemodynamic changes 
were observed in group 1. After treatment, groups 2 and 3 had significant de- 
creases in MAP compared with fatigued values (121 [10] vs 107 [10] mm Hg, 
P = 0.022 and 122 [9] vs 109 [11] mm Hg, P = 0.023, respectively) and group 1 
MAP values (123 [9] vs 107 [10] and 123 [9] vs 109 [11] mm Hg; both, P= 0.019). 
The posttreatment MAP of group 4 (124 [10] mm Hg) was significantly greater than 
that of group 2 (107 [10] mm Hg) and group 3 (109 [11] mm Hg; both, P < 0.05) 
(Table I). 
The Pdi, %Edi-cru, and %Edi-cost values obtained for all 4 groups at low- and 
high-frequency stimulation are shown in Table II. When fatigue was established 
in each group, Pdi at low-frequency (20 Hz) stimulation decreased significantly 
from baseline in all groups (P < 0.05), while Pdi at high-frequency (100 Hz) stim- 
ulation did not change significantly (P = NS). After treatment, Pdi at both 
stimuli levels increased significantly from fatigued values in groups 2, 3, and 4 
(P < 0.05). The increase in Pdi at both stimuli levels was significantly greater in 
group 4 than in the other 3 groups (all, P < 0.05). In group 1, which received 
no study drugs, Pdi at 20 Hz stimulation did not increase from fatigued values 
(P = NS). No changes in %Edi-cru and %Edi-cost at either stimulation level were 
observed in any group throughout the experiment. 
DISCUSSION 
The spontaneous, natural rate of phrenic nerve discharge occurs mainly in the 
low-frequency ranges (ie, 5-30 Hz), making low-frequency fatigue of particular 
clinical importance. 14In this study, therefore, the effects of olprinone mono- 
therapy, or olprinone in combination with dopamine, on contractil ity during 
diaphragmatic fatigue induced by 20 Hz stimulation (ie, low-frequency fa- 
tigue) were studied. In group 1, which received no study drugs, diaphragmatic 
contractil ity (assessed by Pdi) at 20 Hz stimulation did not increase from 
fatigued values. These results were in agreement with previous tudies we have 
conducted. 5-7 Because the dogs were anesthetized with pentobarbital, the com- 
bined effects of pentobarbital nd the study drugs on diaphragmatic contractil- 
ity were also examined. However, it has been reported that pentobarbital, in the 
dose used in this experiment (2 mg/kg • h), does not affect contractil ity of the 
diaphragm. 15This was in accordance with our findings that pentobarbital- 
anesthetized dogs that did not receive a study drug were associated with no 
significant change in Pdi after fatigue was established. 
Olprinone increases cardiac muscle contractil ity by selectively inhibiting 
phosphodiesterase 3 and accumulating cyclic adenosine monophosphate intra- 
cellularly, which induces the activation of the calcium ion (Ca 2+) transport from 
the sarcoplasmic reticulum. 16,17 In addition to these pharmacologic properties, 
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Table I. Mean (SD) hemodynamic data at baseline, in fatigued diaphragm, and after 
treatment in pentobarbital-anesthetized dogs in group 1 (no study drug), 
group 2 (olprinone 0.3 Mg/kg • rain), group 3 (olprinone plus dopamine 
2 Mg/kg • rain), and group 4 (olprinone plus dopamine 5 Mg/kg • rain) (N = 28). 
Groups 2, 3, and 4 received an inital 10 Mg/kg dose of olprinone. 
Fatigued After 
Variable Group Baseline Diaphragm Treatment 
HR, bpm 1 142 (10) 140 (12) 140 (10) 
2 140 (10) 140 (8) 152 (6) *t# 
3 140 (11) 139 (10) 153 (10) *t# 
4 142 (11) 141 (11) 160 (11) *t# 
MAP, mm Hg 1 123 (8) 123 (8) 123 (9) 
2 122 (8) 121 (10) 107 (10) *t# 
3 121 (10) 122 (9) 109 (11) *t~ 
4 123 (7) 1 23 (9) 1 24 (10) §11 
RAP, mm Hg 1 5 (2) 5 (2) 5 (2) 
2 5 (1) 5 (2) 5 (2) 
3 5 (1) 5 (1) 5 (1) 
4 5 (2) 5 (2) 5 (2) 
MPAP, mm Hg 1 12 (2) 12 (1) 12 (2) 
2 12 (1) 12 (2) 10 (1) *t# 
3 12 (1) 12 (2) 10 (1) *t# 
4 12 (1) 12 (2) 12 (1)§11 
PAOP, mm Hg 1 8 (2) 8 (2) 8 (2) 
2 8 (2) 8 (1) 6 (1) *t* 
3 8 (2) 8 (1) 6 (1) *t* 
4 8 (2) 8 (1) 8 (2)§11 
CO, L/min 1 2.0 (0.2) 2.0 (0.3) 2.0 (0.3) 
2 2.1 (0.4) 2.1 (0.4) 3.0 (0.4) *t# 
3 2.0 (0.3) 2.1 (0.3) 3.1 (0.3) *t# 
4 1.9 (0.2) 2.0 (0.2) 3.5 (0.2)*t#§ll 
HR = heart rate; MAP = mean arterial pressure; RAP = right atrial pressure; MPAP = mean 
arterial pressure; PA©P = pulmonary artery occlusion pressure; CO = cardiac output. 
*P < 0.05 versus baseline, tp < 0.05 versus fatigued diaphragm. 
~P < 0.05 versus group 1. §P < 0.05 versus group 2. 
lip < 0.05 versus group 3. 
pulmonary 
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Table II. Mean (SD) changes in transdiaphragmatic pressure (Pdi), electrical activity 
of the crural part of the diaphragm (%Ediicru), and electrical activity of the 
costal part of the diaphragm (%Ediicost) at baseline, in fatigued diaphragm, 
and after treatment in group 1 (no study drug), group 2 (olprinone 0.3 Mg/ 
kg • min), group 3 (olprinone plus dopamine 2 Mg/kg • min), and group 4 
(olprinone plus dopamine 5 Mg/kg • min) (N = 28). Groups 2, 3, and 4 
received an intial 10 Mg/kg dose of olprinone. 
Fatig ued After 
Variable Group Baseline Diaphragm Treatment 
Pdi, cm H20 
20 Hz stimulation 
100 Hz stimulation 
%Edi-cru 
20 Hz stimulation 
100 Hz stimulation 
%Edi-cost 
20 Hz stimulation 
100 Hz stimulation 
1 15.6 (2.2) 11.7 (2.4)* 11.9 (2.5)* 
2 15.4 (1.5) 11.6 (1.3)* 21.8 (2.0) *t# 
3 15.5 (2.0) 11.6 (1.8)* 22.2 (1.8) *t# 
4 15.7 (1.4) 12.0 (1.4)* 25.9 (1.9) *t#§ll 
1 22.1 (2.4) 21.9 (2.3) 22.0 (2.1) 
2 22.1 (2.0) 22.0 (2.2) 29.0 (1.9) *t# 
3 22.2 (1.9) 22.1 (2.0) 29.3 (2.2) *t# 
4 22.0 (2.2) 21.8 (2.2) 31.7 (2.4) *t#§ll 
I 100 (0.0) 99.1 (6.1) 99.1 (6.1) 
2 100 (0.0) 99.1 (6.1) 100.2 (5.2) 
3 100 (0.0) 97.9 (3.9) 101.4 (3.8) 
4 100 (0.0) 98.9 (3.0) 100.2 (5.2) 
I 100 (0.0) 99.6 (2.1) 99.6 (2.1) 
2 100 (0.0) 98.9 (2.0) 99.4 (2.5) 
3 100 (0.0) 99.4 (2.5) 99.4 (2.5) 
4 100 (0.0) 99.8 (2.0) 99.8 (2.0) 
1 100 (0.0) 98.9 (3.0) 98.9 (3.0) 
2 100 (0.0) 99.1 (6.1) 99.1 (6.1) 
3 I00 (0.0) 98.6 (3.9) 99.1 (6.1) 
4 100 (0.0) 99.1 (3.0) 100.2 (5.2) 
1 100 (0.0) 99.8 (2.0) 99.8 (2.0) 
2 I00 (0.0) 98.9 (2.0) 99.6 (2.1) 
3 100 (0.0) 99.4 (2.5) 99.4 (2.5) 
4 100 (0.0) 99.8 (2.0) 99.8 (2.0) 
*P < 0.05 versus baseline. 
SP < 0.05 versus group 1. 
lip < 0.05 versus group 3. 
tp < 0.05 versus fatigued diaphragm. 
§P < 0.05 versus group 2. 
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olprinone might be useful for improving contractility in a fatigued iaphragm. 7 
In the present study, we showed that Pdi at 20 Hz and 100 Hz stimulation 
increased significantly from fatigued values (both, P < 0.05) with an infusion of 
olprinone (group 2). In preliminary studies we performed, 7,18 to clarify the 
mechanism responsible for the efficacy of olprinone in augmenting contractil- 
ity of fatigued iaphragm, the combination of olprinone and nicardipine, a cal- 
cium channel blocker that inhibits Ca 2+ influx into the diaphragm uscle, was 
administered. We found that the enhanced iaphragmatic contractility with 
olprinone was abolished with an infusion of nicardipine, suggesting that olpri- 
none increases contractility in a fatigued iaphragm by influencing Ca 2+ trans- 
port across the cell membrane. 
It is known that olprinone produces positive inotropic and vasodilating ef- 
fects, 16,17 thereby inducing severe hypotension during high-dose @0.3 1Jg/kg • min) 
olprinone administration. 8 To avoid hypotension, dopamine was added to olpri- 
none in the present study. In group 3 (olprinone 0.3 1Jg/kg • min plus dopamine 
2 1Jg/kg • min), MAP decreased significantly from baseline (P < 0.05) and Pdi at 
20 Hz and 100 Hz stimulation increased significantly from fatigued values (both, 
P< 0.05). In group 4 (olprinone 0.3 1Jg/kg • min plus dopamine 5 1Jg/kg • min), MAP 
did not decrease from baseline and Pdi at both stimuli increased significantly 
from fatigued values (both, P < 0.05). Therefore, in this study, the addition of 
dopamine 5 1Jg/kg • min was associated with the prevention of hypotension 
caused by olprinone therapy. 
We also found that Pdi at 20 Hz and 100 Hz stimulation i creased significantly 
from fatigued values with an infusion of olprinone alone and combined with 
dopamine and that the increases in Pdi were largest when the study drugs were 
combined. These findings uggest that dopamine added to olprinone increases 
the contractility of fatigued iaphragm in a dose-dependent manner. The pre- 
cise mechanism underlying these findings is unknown. Diaphragmatic contrac- 
tility depends on the energy supplied to the diaphragm, which is related to the 
blood supply to the diaphragm. CO is one of the major factors for determining 
blood flow to the diaphragm. 19Diaphragmatic fatigue occurs when more energy 
is used by the muscles than is supplied by the blood. 17 Therefore, the increase 
in CO we observed in groups 2, 3, and 4 might have led to an increase in blood 
flow to the diaphragm, which might have then increased the contractility of 
fatigued iaphragm by increasing oxygen delivery to the diaphragm. 
Our findings on improving diaphragmatic fatigue by administering olprinone 
monotherapy and in combination with dopamine must be considered within 
the context of the study limitations. Diaphragmatic fatigue occurs in a number 
of clinical conditions in which the work of breathing is increased, such as air- 
way obstruction, asthma, or chronic obstructive pulmonary disease. 1,2 In this 
study, diaphragmatic fatigue was induced by intermittent supramaximal bilat- 
eral electrophrenic stimulation at a frequency of 20 Hz, 11 which differs from the 
fatigue produced by certain pathological conditions. 1,2 The experimental fa- 
tigue of the diaphragm was not associated with an increased load of the air- 
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way. We have already assessed the effect of olprinone on diaphragm muscle 
function during fatigue induced by 20 Hz stimulation. 7 Also, blood flow to the 
diaphragm, which can affect d iaphragmatic  contractil ity, was not measured in 
the present study. However, Aubier et a111 found that dopamine 10 pg/kg • min 
increased both diaphragmatic  blood flow (assessed by t imed volume collec- 
tions of the inferior phrenic venous effluent) and diaphragmatic  contracti l i ty 
(assessed by Pdi). Another limitation of the study was our small sample size. 
However, when power analysis was performed, a total of 7 dogs in each group 
was found to be sufficient to detect a significant difference with 0¢ of 0.05 and 
80% power of the study. Lastly, the s tudy was not blinded. Further studies 
should consider these limitations. 
CONCLUSIONS 
Olprinone t reatment  administered concomitant ly  with dopamine 5 pg/kg • min 
improved contracti l i ty in fatigued d iaphragms and was not associated with 
hypotension in pentobarbita l -anesthet ized dogs. In this study, olprinone mono- 
therapy or olprinone 0.3 pg/kg • min plus dopamine 2 pg/kg • min improved con- 
tracti l ity significantly. It was also associated with significant decreases in MAP. 
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